Literature DB >> 16671340

Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure.

Satoshi Hoshide1, Kazuomi Kario, Joji Ishikawa, Kazuo Eguchi, Kazuyuki Shimada.   

Abstract

Cilnidipine is a novel and unique 1,4-dydropyridine derivative calcium antagonist that exerts potent inhibitory actions not only on L-type but also on N-type voltage-dependent calcium channels. Blockade of the neural N-type calcium channel inhibits the secretion of norepinephrine from peripheral neural terminals and depresses sympathetic nervous system activity. The purpose of this study was to assess the effect of cilnidipine and amlodipine on ambulatory blood pressure (BP) levels. We performed 24-h ambulatory BP monitoring before and after once-daily use of cilnidipine (n=55) and amlodipine (n=55) in 110 hypertensive patients. Both drugs significantly reduced clinic and 24-h systolic BP (SBP) and diastolic BP (DBP) (p < 0.005). However, the reductions of 24-h (-1.19+/-6.78 vs. 1.55+/-6.13 bpm, p=0.03), daytime (-1.58+/-6.72 vs. 1.68+/-7.34 bpm, p=0.02) and nighttime (-1.19+/-5.72 vs. 1.89+/-6.56 bpm, p=0.01) pulse rate (PR) were significantly greater in the cilnidipine group than the amlodipine group. There was no correlation between the degree of daytime SBP change and that of daytime PR change after amlodipine treatment (r=-0.08, n.s.), but there was a significant negative correlation between the degree of daytime SBP change and that of day-time PR change after cilnidipine treatment (r=-0.27, p<0.05). N-type calcium channel blockade by cilnidipine may not cause reflex tachycardia, and may be useful for hypertensive treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16671340     DOI: 10.1291/hypres.28.1003

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  13 in total

1.  The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.

Authors:  Shizuka Aritomi; Hajime Koganei; Hirotaka Wagatsuma; Akira Mitsui; Tetsuya Ogawa; Kosaku Nitta; Tomoyuki Konda
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  Resting heart rate and the risk of developing impaired fasting glucose and diabetes: the Kailuan prospective study.

Authors:  Liang Wang; Liufu Cui; Yanxue Wang; Anand Vaidya; Shuohua Chen; Caifeng Zhang; Ying Zhu; Dongqing Li; Frank B Hu; Shouling Wu; Xiang Gao
Journal:  Int J Epidemiol       Date:  2015-05-22       Impact factor: 7.196

Review 3.  The fourth-generation Calcium channel blocker: cilnidipine.

Authors:  K Sarat Chandra; G Ramesh
Journal:  Indian Heart J       Date:  2013-12

4.  L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.

Authors:  Shizuka Aritomi; Tomoyuki Konda; Michihiro Yoshimura
Journal:  Heart Vessels       Date:  2011-10-12       Impact factor: 2.037

5.  A Comparative Study on Clinical and Biochemical Parameters in Amlodipine and Cilnidipine Treated Hypertensive Patients.

Authors:  Kiran Shetty; Ranjan Shetty; Lakshminarayana Bairy; Pragna Rao; Amruth Kiran; Manjunath Shetty; Vidya Nayak
Journal:  J Clin Diagn Res       Date:  2017-05-01

6.  L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.

Authors:  Masanori Abe; Noriaki Maruyama; Hiroko Suzuki; Atsushi Inoshita; Yoshinori Yoshida; Kazuyoshi Okada; Masayoshi Soma
Journal:  Heart Vessels       Date:  2012-08-23       Impact factor: 2.037

7.  Comparison of Plasma Levels of Renin, Vasopressin and Atrial Natriuretic Peptide in Hypertensive Amlodipine Induced Pedal Oedema, Non-Oedema and Cilnidipine Treated Patients.

Authors:  Kiran Shetty; Ranjan Shetty; Pragna Rao; Mamatha Ballal; Amruth Kiran; Sravan Reddy; Umesh Pai; Jyothi Samanth
Journal:  J Clin Diagn Res       Date:  2017-06-01

8.  L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.

Authors:  Tomohiko Kanaoka; Kouichi Tamura; Hiromichi Wakui; Masato Ohsawa; Kengo Azushima; Kazushi Uneda; Ryu Kobayashi; Tetsuya Fujikawa; Yuko Tsurumi-Ikeya; Akinobu Maeda; Mai Yanagi; Yoshiyuki Toya; Satoshi Umemura
Journal:  Int J Mol Sci       Date:  2013-08-16       Impact factor: 5.923

9.  Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study.

Authors:  Kazuomi Kario; Ikuo Saito; Toshio Kushiro; Satoshi Teramukai; Yoshihiro Mori; Katsutoshi Hiramatsu; Fumiaki Kobayashi; Kazuyuki Shimada
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-05-31       Impact factor: 3.738

10.  Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot study.

Authors:  Hiroko Abe; Tomoya Mita; Risako Yamamoto; Koji Komiya; Minako Kawaguchi; Yuko Sakurai; Tomoaki Shimizu; Chie Ohmura; Fuki Ikeda; Ryuzo Kawamori; Yoshio Fujitani; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2012-10-22       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.